论文部分内容阅读
目的:对比TP方案与CAP方案治疗老年晚期非小细胞肺癌的临床疗效、生存期及毒副反应。方法:统计分析用TP(紫杉醇、顺铂)方案及CAP(环磷酰胺、阿霉素、顺铂)方案治疗65例老年晚期非小细胞肺癌病例的临床资料。结果:TP组有效率为51.5%,中位生存时间10个月;CAP组有效率为28.1%,中位生存时间6个月。毒副反应主要为骨髓抑制、消化道反应及脱发。结论:TP方案治疗老年晚期非小细胞肺癌疗效优于CAP方案,毒副反应轻,可作为临床一线化疗方案。
OBJECTIVE: To compare the clinical efficacy, survival and toxicity of TP regimen and CAP regimen in the treatment of elderly patients with advanced non-small cell lung cancer. Methods: The clinical data of 65 elderly patients with advanced non-small cell lung cancer (NSCLC) treated with TP (paclitaxel, cisplatin) and CAP (cyclophosphamide, doxorubicin and cisplatin) were statistically analyzed. Results: The effective rate of TP group was 51.5% and the median survival time was 10 months. The effective rate of CAP group was 28.1% and the median survival time was 6 months. Toxicity mainly for bone marrow suppression, gastrointestinal reactions and hair loss. Conclusion: TP regimen is superior to CAP regimen in the treatment of elderly patients with advanced non-small cell lung cancer. It has low toxicity and can be used as a first-line clinical regimen.